According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer ...
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
Rhode Island ranked second for its lung cancer survival rate, with more than 35% living five years post diagnosis. The state ...
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...
The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...
The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...
Researchers at the University of Iowa found that adding high-dose IV vitamin C to chemotherapy helped increase survival in ...
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
Dr. Heba Ismail at Sutter Health’s California Pacific Medical Center has dedicated her career to the early detection and ...
FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...